Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Enanta Pharmaceuticals Inc.
DescriptionOral HCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection; Treat HCV genotype 1 infection; Treat HCV genotype 1b infection; Treat HCV genotype 2 infection; Treat HCV infection
Regulatory Designation U.S. - Fast Track (Treat HCV genotype 1 infection)
PartnerAbbVie Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today